Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Patient Eligibility Cohort 1 (ADV) -Patients with ADV infections (Cohort 1) (pneumonitis, hepatitis, cystitis, and/or colitis) post AlloHSCT with one or more of the following: Increasing or persistent ADV RT-PCR DNA (\> 1000 ADV PCR copies) after 7 days of appropriate anti-viral therapy AND/OR Medical intolerance to anti-viral therapies including one or more of the following: \> grade 2 renal insufficiency secondary to cidofovir and/or other \> grade 2 toxicities secondary to cidofovir AND/OR Known resistance to cidofovir Patient Eligibility (Cohort 2) (CMV) -Patients with CMV infections (pneumonitis, hepatitis, colitis) with one or more of the following: Increasing or persistent CMV RT-PCR DNA (\>1000 copies) after 7 days of appropriate anti-viral therapy AND/OR Medical intolerance to anti-CMV antibiotic therapies: ANC \> 500/mm3 secondary to ganciclovir AND/OR \> grade 2 renal toxicity secondary to either foscarnet or cidofovir AND/OR Known resistance to ganciclovir and/or foscarnet * Consent: written informed consent given (by patient or legal representative) prior to any study related procedures * Performance Status \>30% (Lansky \< 16 yrs and Karnofsky \> 16 years (BOTH COHORTS) * Age: 0.01 to 30.00 years (BOTH COHORTS) * Females of childbearing potential with a negative urine pregnancy test at study entry only (BOTH COHORTS) Donor Eligibility * Related donor available with a T-cell response to the ADV MACS PepTivators (Cohort 1) or CMV MACS PepTivator (Cohort 2). A…